Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: High-Frequency oscillatory ventilation for patients during exudative phase of severe ARDS
Authors: Thummaporn Naorungroj
Warakarn Vilaichone
Surat Tongyoo
Preecha Thamrongpairoj
Chairat Permpikul
Mahidol University
Keywords: Medicine
Issue Date: 1-Jan-2015
Citation: Journal of the Medical Association of Thailand. Vol.98, No.4 (2015), 343-351
Abstract: © 2015, Journal of the Medical Association of Thailand. All rights reserved. Background: High frequency oscillatory ventilation (HFOV) is theoretically ideal for lung protective strategy ventilation (LPSV) in acute respiratory distress syndrome (ARDS). However, recent studies revealed unsatisfactory outcomes. The authors conducted a study to examine this phenomenon in patients with early phase of moderate to severe ARDS. Objective: To evaluate the effectiveness of HFOV in patients with early phase of moderate to severe ARDS. The primary outcome was 30 days all-cause mortality. Material and Method: The study was a matched-case controlled clinical trial performed in the medical intensive care units, Faculty of Medicine, Siriraj Hospital. The authors compared HFOV with LPSV in adult patients with the early phase of ARDS who received mechanical ventilation less than 72 hours and had moderate to severe hypoxemia (PaO<inf>2</inf> /FiO<inf>2</inf> ratio less than or equal 150). Results: Between June 2010 and February 2014, 49 patients with moderate to severe ARDS were included. Fourteen patients who received HFOV were matched with 16 patients who received LPSV. The 30-day mortality in HFOV group was 61.5%; while in control group, 50% (p = 0.53). The authors found use of higher doses of sedative drugs and muscle relaxants in HFOV group. In addition, this group had high-level of mean airway pressure (mPaw). The presence of hemodynamic instability was not different in both groups. Conclusion: In adult patients in the early phase of moderate to severe ARDS who received mechanical ventilation for less than 72 hours, HFOV did not decrease the 30-day mortality. Thus, this support should be only a rescue therapy for refractory hypoxemia cases and in highly selected patients.
ISSN: 01252208
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.